These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 36594091)

  • 1. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
    Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
    Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
    Yu XD; Wang JW
    Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipids at the Crossroads of NAFLD and Senescence.
    Nikolova-Karakashian M
    Adv Cancer Res; 2018; 140():155-190. PubMed ID: 30060808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis.
    Apostolopoulou M; Gordillo R; Koliaki C; Gancheva S; Jelenik T; De Filippo E; Herder C; Markgraf D; Jankowiak F; Esposito I; Schlensak M; Scherer PE; Roden M
    Diabetes Care; 2018 Jun; 41(6):1235-1243. PubMed ID: 29602794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats.
    Yue F; Xia K; Wei L; Xing L; Wu S; Shi Y; Lam SM; Shui G; Xiang X; Russell R; Zhang D
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1978-1989. PubMed ID: 32027419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipidomics in non-alcoholic fatty liver disease.
    Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
    World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
    Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.
    Hajduch E; Lachkar F; Ferré P; Foufelle F
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD.
    Poss AM; Summers SA
    Front Endocrinol (Lausanne); 2020; 11():505. PubMed ID: 32849291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease: Insights from sphingolipidomics.
    Montefusco DJ; Allegood JC; Spiegel S; Cowart LA
    Biochem Biophys Res Commun; 2018 Oct; 504(3):608-616. PubMed ID: 29778532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ketogenic diet prevents steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation and protein kinase C activity in male rat liver.
    Jani S; Da Eira D; Stefanovic M; Ceddia RB
    J Physiol; 2022 Sep; 600(18):4137-4151. PubMed ID: 35974660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
    Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
    Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concise review of lipidomics in nonalcoholic fatty liver disease.
    Béland-Bonenfant S; Rouland A; Petit JM; Vergès B
    Diabetes Metab; 2023 May; 49(3):101432. PubMed ID: 36781065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.